Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RO 7617991

Next Previous
X
Search
Drug Profile

RO 7617991

Alternative Names: RO-7617991

Latest Information Update: 11 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 30 Aug 2024 Genentech withdrew a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second line therapy or greater), due to an internal Sponsor decision. The decision was not due to any safety or efficacy concerns with the study drug (IV, Infusion) (NCT06372574)
  • 18 Apr 2024 Preclinical trials in Solid tumours in USA (IV) prior to April 2024
  • 18 Apr 2024 Genentech plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second line therapy) in July 2024 (IV) (NCT06372574)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top